Ontramab 440mg Injection

About

Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 overexpression is observed in a subset of aggressive breast and gastric cancers, driving tumor growth and progression. By binding to HER2, trastuzumab inhibits the proliferation of tumor cells that overexpress HER2, mediates antibody-dependent cell-mediated cytotoxicity (ADCC), and prevents HER2 cleavage, thereby blocking critical signaling pathways. This highly targeted therapy significantly improves clinical outcomes, including survival rates and disease-free survival, in patients with HER2-positive cancers, either as monotherapy or in combination with chemotherapy. It is administered intravenously as a cornerstone of treatment.

Uses

• Treatment of HER2-positive metastatic breast cancer.
• Adjuvant treatment of HER2-positive early breast cancer.
• Treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
• Used in combination with chemotherapy or other targeted therapies.

Directions For Use

Administer intravenously under the supervision of an oncologist. Dosage and frequency are determined by body weight or fixed dose, and the specific cancer indication.

Benefits

• Targets HER2-positive cancer cells specifically.
• Significantly improves survival rates in HER2-positive cancers.
• Reduces the risk of cancer recurrence.
• Can be used in various stages of HER2-positive disease.
• Well-established efficacy in clinical trials.
• Offers a personalized treatment approach.

Side Effects

• Cardiotoxicity (e.g., congestive heart failure)
• Infusion-related reactions (fever, chills, nausea)
• Diarrhea
• Fatigue
• Headache
• Rash
• Nausea and vomiting
• Abdominal pain
• Myelosuppression (less common than with chemotherapy)
• Cough
• Dyspnea
• Peripheral edema

Safety Measures

• Alcohol - No specific direct interaction with alcohol, but it's generally advisable to limit or avoid alcohol during cancer treatment to manage overall health and potential side effects.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm, including oligohydramnios and fetal renal impairment. Effective contraception is required.
• Breastfeeding - Breastfeeding is not recommended during trastuzumab treatment and for a period after, due to the potential for serious adverse reactions in the infant.
• Liver - No specific dose adjustment is generally required for liver impairment, but caution is advised.
• Kidney - No specific dose adjustment is generally required for kidney impairment, but caution is advised.
• Lung - Rare but serious pulmonary toxicity, including interstitial pneumonitis and acute respiratory distress syndrome, has been reported. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.